Close

Dr Magdalena Bielecka

Lab Manager and Training Coordinator

United Kingdom

Magdalena currently provides support within CL3 suite as a laboratory manager and a CL3 training coordinator. Her previous experience includes managing Schedule 5 laboratory and carrying out research as part of her Scientific Officer role since joining LSHTM in 2019.

 

She has extensive work experience with infectious agents under biosafety containment levels 2 and 3. This has been acquired through postdoctoral placements at the University of Southampton on Neisseria meningitidis and Mycobacterium tuberculosis and her Ph.D. studies on Listeria at the University of Edinburgh and a current placement at LSHTM working with mycobacteria and Shigella spp.

Affiliations

Faculty of Infectious and Tropical Diseases

Research

Magdalena's main research interests focus on host-pathogen interactions.

 

One of her previous contributions included developing a novel 3-dimensional model system for Mycobacterium tuberculosis (Mtb) by using the bioelectrospraying technique, which incorporates extracellular matrix (ECM), Mtb and different human cells to form an in vitro granuloma model system, when she joined Professor Paul Elkington’s lab in 2013 at the University of Southampton. Using this approach, she studied the factors that control the secretion of cytokines and metalloproteinases (MMPs) as well as the role of ECM in regulating the host-pathogen interaction. She also investigated the effect of antibiotics on Mtb killing using the 3-D model and studied multi-drug resistant TB (MDR-TB) in the context of the host.

 

In 2019-2022, working with Professor Serge Mostowy at LSHTM, Magdalena was involved in several research projects, in which she investigated host-pathogen interactions using zebrafish model of infection.

Research Area
Microbiology
Innate immunity
Cell biology
Disease and Health Conditions
Tuberculosis

Selected Publications

Three-Dimensional Culture Modelling Reveals Divergent Mycobacterium tuberculosis Virulence and Antimicrobial Treatment Response
BIELECKA, MK; Tezera, LB; Konstantinopoulou, E; Casali, N; Katsamenis, OL; Gonzalo, X; Drobniewski, F; Elkington, PT;
2024
Cellular Microbiology
Shigella induces epigenetic reprogramming of zebrafish neutrophils.
Gomes, MC; Brokatzky, D; BIELECKA, MK; Wardle, FC; MOSTOWY, S;
2023
Science advances
Zebrafish null mutants of Sept6 and Sept15 are viable but more susceptible to Shigella infection.
Torraca, V; BIELECKA, MK; Gomes, MC; Brokatzky, D; Busch-Nentwich, EM; MOSTOWY, S;
2023
Cytoskeleton
Septins promote caspase activity and coordinate mitochondrial apoptosis.
Van Ngo, H; ROBERTIN, S; Brokatzky, D; BIELECKA, MK; Lobato-Márquez, D; Torraca, V; MOSTOWY, S;
2022
Cytoskeleton
Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis.
Garay-Baquero, DJ; White, CH; Walker, NF; Tebruegge, M; Schiff, HF; Ugarte-Gil, C; Morris-Jones, S; Marshall, BG; Manousopoulou, A; Adamson, J; Vallejo, AF; BIELECKA, MK; Wilkinson, RJ; Tezera, LB; Woelk, CH; Garbis, SD; Elkington, P;
2020
JCI insight
Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α.
Tezera, LB; BIELECKA, MK; Ogongo, P; Walker, NF; Ellis, M; Garay-Baquero, DJ; Thomas, K; Reichmann, MT; Reichmann, MT; Johnston, DA; Wilkinson, KA; Ahmed, M; Jogai, S; Jayasinghe, SN; Wilkinson, RJ; Mansour, S; Thomas, GJ; Ottensmeier, CH; Leslie, A; Elkington, PT;
2020
eLife
Advanced cellular systems to study tuberculosis treatment.
BIELECKA, MK; Elkington, P;
2018
Current opinion in pharmacology
Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathology.
Brace, PT; Tezera, LB; BIELECKA, MK; Mellows, T; Garay, D; Tian, S; Rand, L; Green, J; Jogai, S; Steele, AJ; Millar, TM; Sanchez-Elsner, T; Friedland, JS; Proud, CG; Elkington, PT;
2017
PLoS pathogens
See more information